The Application of CRISPR-Cas System in Glioblastoma Research and Treatment

Abstract

Glioblastoma is a malignant brain cancer with high mortality. Currently, there is no effective treatment that can effectively improve the survival of patients. Traditional gene editing tools, such as Zinc finger nuclease, RNAi and translational activator-like effector nucleases (TALENTS), have shown their advantages in treating glioblastoma. However, they have the disadvantages of high cost and difficult to operate. In recent years, with the discovery and development of the CRISPR-Cas system, its easy to design, inexpensive, and high flexibility make it gradually become a widely used gene editing tool and provide a strong boost for the research of glioblastoma. This article reviews the recent literature and summarizes the application of the CRISPR Cas system in the model establishment and therapy development of glioblastoma.